Zdrowie i gospodarka · 26/02/2014

FDA Announces Public Hearing on Generic Drug Regulatory Science Initiatives

The FDA is hosting a public hearing to gather input from various stakeholders on research priorities for generic drugs, as part of its commitment to develop an annual list of regulatory science initiatives under the Generic Drug User Fee Amendments of 2012 (GDUFA). The hearing will inform the development of the FY 2015 Regulatory Science Plan.